157 related articles for article (PubMed ID: 10503166)
1. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial.
Gordon M; Bihari B; Goosby E; Gorter R; Greco M; Guralnik M; Mimura T; Rudinicki V; Wong R; Kaneko Y
J Med; 1998; 29(5-6):305-30. PubMed ID: 10503166
[TBL] [Abstract][Full Text] [Related]
2. A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3.
Gordon M; Guralnik M; Kaneko Y; Mimura T; Goodgame J; DeMarzo C; Pierce D; Baker M; Lang W
J Med; 1995; 26(5-6):193-207. PubMed ID: 8721897
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide Celgene Corp.
Bruyn GA
IDrugs; 1998 Aug; 1(4):490-500. PubMed ID: 18465584
[TBL] [Abstract][Full Text] [Related]
4. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
5. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
6. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
8. [Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer].
Taguchi T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):387-93. PubMed ID: 6349538
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
de Mendoza C; Soriano V; Pérez-Olmeda M; RodrÃguez-Rosado R; González-Lahoz J
J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
[TBL] [Abstract][Full Text] [Related]
10. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
11. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
13. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
15. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
16. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
[TBL] [Abstract][Full Text] [Related]
17. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
18. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer.
Hazama S; Watanabe S; Ohashi M; Yagi M; Suzuki M; Matsuda K; Yamamoto T; Suga Y; Suga T; Nakazawa S; Oka M
Anticancer Res; 2009 Jul; 29(7):2611-7. PubMed ID: 19596936
[TBL] [Abstract][Full Text] [Related]
20. The shiitake mushroom-derived immuno-stimulant lentinan protects against murine malaria blood-stage infection by evoking adaptive immune-responses.
Zhou LD; Zhang QH; Zhang Y; Liu J; Cao YM
Int Immunopharmacol; 2009 Apr; 9(4):455-62. PubMed ID: 19189863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]